AU2074201A - Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer - Google Patents

Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer

Info

Publication number
AU2074201A
AU2074201A AU20742/01A AU2074201A AU2074201A AU 2074201 A AU2074201 A AU 2074201A AU 20742/01 A AU20742/01 A AU 20742/01A AU 2074201 A AU2074201 A AU 2074201A AU 2074201 A AU2074201 A AU 2074201A
Authority
AU
Australia
Prior art keywords
kits
assessment
therapy
prevention
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU20742/01A
Inventor
Allison Berger
James Deeds
Robert Schlegel
Xumei Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
MILLENNIUM PREDICTIVE MEDICINE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MILLENNIUM PREDICTIVE MEDICINE filed Critical MILLENNIUM PREDICTIVE MEDICINE
Publication of AU2074201A publication Critical patent/AU2074201A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57411—Specifically defined cancers of cervix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU20742/01A 1999-12-08 2000-12-08 Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer Abandoned AU2074201A (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US16968199P 1999-12-08 1999-12-08
US60169681 1999-12-08
US17135099P 1999-12-21 1999-12-21
US60171350 1999-12-21
US18931500P 2000-03-14 2000-03-14
US60189315 2000-03-14
US20379100P 2000-05-12 2000-05-12
US60203791 2000-05-12
US21060000P 2000-06-09 2000-06-09
US60210600 2000-06-09
US22011400P 2000-07-21 2000-07-21
US60220114 2000-07-21
PCT/US2000/033312 WO2001042467A2 (en) 1999-12-08 2000-12-08 Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer

Publications (1)

Publication Number Publication Date
AU2074201A true AU2074201A (en) 2001-06-18

Family

ID=27558590

Family Applications (1)

Application Number Title Priority Date Filing Date
AU20742/01A Abandoned AU2074201A (en) 1999-12-08 2000-12-08 Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer

Country Status (2)

Country Link
AU (1) AU2074201A (en)
WO (1) WO2001042467A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576755B1 (en) 1997-09-10 2003-06-10 Zymogenetics, Inc. Beta-defensins
US20030144225A1 (en) * 2001-12-28 2003-07-31 Karras James G. Antisense modulation of macrophage inflammatory protein 3-alpha expression
EP1637541B1 (en) * 1999-09-01 2010-03-03 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2001238144A1 (en) * 2000-02-09 2001-08-20 Agensys, Inc. 83p5g4: a tissue specific protein highly expressed in prostate cancer
AU2001245953A1 (en) * 2000-03-24 2001-10-08 Genzyme Corporation Oncogenic osteomalacia-related gene 1
WO2002002759A2 (en) * 2000-06-29 2002-01-10 Millennium Pharmaceuticals, Inc. A human alpha/beta hydrolase family member (32225) and uses thereof
WO2001083753A2 (en) * 2000-05-03 2001-11-08 Millennium Pharmaceuticals, Inc. Molecules of the nbs/lrr protein family and uses thereof
US7034135B2 (en) 2000-05-03 2006-04-25 Millennium Pharmaceuticals, Inc. Molecules of the NBS/LRR protein family and uses thereof
WO2001094417A2 (en) * 2000-06-09 2001-12-13 Lexicon Genetics Incorporated Novel human seven transmembrane proteins and polynucleotides encoding the same
DE60134178D1 (en) 2000-07-28 2008-07-03 Ulrich Wissenbach TRP8 CANCER MARKER
AU2001294545A1 (en) * 2000-09-08 2002-03-22 Millennium Pharmaceuticals, Inc. 27877, a novel phospholipase and uses therefor
CA2425643A1 (en) * 2000-10-11 2002-04-18 Avalon Pharmaceuticals Cancer-linked genes as targets for chemotherapy
WO2002046477A2 (en) 2000-12-07 2002-06-13 Chiron Corporation Endogenous retroviruses up-regulated in prostate cancer
US7119185B2 (en) * 2000-12-21 2006-10-10 Trustees Of The University Of Pennsylvania Hormonally up-regulated, neu-tumor-associated kinase
US20030148920A1 (en) * 2000-12-27 2003-08-07 Steven Rosen Sulfatases and methods of use thereof
US20060063230A1 (en) 2000-12-27 2006-03-23 Roman Naworth Sulfatases and methods of use thereof
WO2002066623A2 (en) * 2001-02-21 2002-08-29 Bayer Aktiengesellschaft Regulation of human phosphatidic acid-preferring phospholipase a1
WO2002081642A2 (en) * 2001-04-06 2002-10-17 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
AU2002258626B2 (en) 2001-04-10 2007-01-18 Agensys, Inc. Nucleid acid and corresponding protein entitled 158P3D2 useful in treatment and detection of cancer
EP1573024A4 (en) 2001-04-10 2007-08-29 Agensys Inc Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
AU2002308139A1 (en) * 2001-04-12 2002-10-28 Bayer Aktiengesellschaft Regulation of human methionine aminopeptidase-like protein
US7335467B2 (en) * 2001-05-15 2008-02-26 Ludwig Institute For Cancer Research Breast cancer antigens
AU2003202543A1 (en) * 2002-01-07 2003-07-24 Bayer Aktiengesellschaft Human phosphatidic acid phosphatase type 2-like protein
EP1532161B1 (en) 2002-06-13 2012-02-15 Novartis Vaccines and Diagnostics, Inc. Vectors for expression of hml-2 polypeptides
WO2004001060A2 (en) 2002-06-20 2003-12-31 Bristol-Myers Squibb Company Identification and regulation of a g-protein coupled receptor, rai-3
WO2004002514A1 (en) * 2002-06-26 2004-01-08 Takeda Pharmaceutical Company Limited Preventives/remedies for cancer
EP1565581B1 (en) * 2002-08-20 2011-08-10 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
EP3257509A1 (en) * 2003-02-12 2017-12-20 Georgetown University Use of artemisinin and related compounds for treating anorectal squamous cell cancer induced by human papilloma virus
WO2004087957A2 (en) * 2003-04-03 2004-10-14 Oncomethylome Sciences S.A. Hypermethylated genes and cervical cancer
US20050136451A1 (en) * 2003-10-06 2005-06-23 Li Yan Hypoxia responsive human CNGH 0002 genes and polypeptides
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
EP1819835B1 (en) 2004-12-08 2010-08-04 Gen-Probe Incorporated Detection of nucleic acids from multiple types of human papillomaviruses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9616429D0 (en) * 1996-08-05 1996-09-25 Quantum Biosystems Ltd Assessment of cervical cells
US5858683A (en) * 1996-08-30 1999-01-12 Matritech, Inc. Methods and compositions for the detection of cervical cancer
WO2001042792A2 (en) * 1999-12-08 2001-06-14 Millennium Pharmaceuticals, Inc. Diagnosis of cervical cancer using marker proteins

Also Published As

Publication number Publication date
WO2001042467A2 (en) 2001-06-14
WO2001042467A3 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
AU2074201A (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
AU2001229340A1 (en) Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU2001241541A1 (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
AU2002337657A1 (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
AU2002322280A1 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU4592601A (en) Novel genes, compositions, kits, and method for identification, assessment, prevention, and therapy of ovarian cancer
AU2001236519A1 (en) Identification, assessment, prevention, and therapy of prostate cancer
AU2001251613A1 (en) Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers
AU7994200A (en) Compositions and methods for therapy and diagnosis of prostate cancer
AU2001268259A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2001269766A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2002365166A1 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of rheumatoid arthritis
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
AU2495200A (en) Compositions and methods for the treatment of tumor
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
AU2003226676A1 (en) Methods and compositions for the identification, assessment, and therapy of small cell lung cancer
AU7701100A (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
AU2001280982A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2001245295A1 (en) Methods and compositions for the identification, assessment, prevention and therapy of human cancers
AU2001268467A1 (en) Identification of genes and compounds for treatment of cancer
AU2001252945A1 (en) Compositions and methods for therapy and diagnosis of colon cancer
AU2074101A (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
AU2001245987A1 (en) Compositions and methods for gene therapy
WO2001079164A3 (en) N-substituted dithiocarbamates for the treatment of biological disorders

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase